- Home
- DJCO vs WVE Comparison
DJCO vs WVE Comparison
Compare DJCO & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DJCO
- WVE
- Stock Information
- Founded
- DJCO 1987
- WVE 2012
- Country
- DJCO United States
- WVE Singapore
- Employees
- DJCO N/A
- WVE N/A
- Industry
- DJCO Newspapers/Magazines
- WVE Biotechnology: Pharmaceutical Preparations
- Sector
- DJCO Consumer Discretionary
- WVE Health Care
- Exchange
- DJCO Nasdaq
- WVE Nasdaq
- Market Cap
- DJCO 793.7M
- WVE 939.3M
- IPO Year
- DJCO N/A
- WVE 2015
- Fundamental
- Price
- DJCO $397.88
- WVE $6.62
- Analyst Decision
- DJCO
- WVE Strong Buy
- Analyst Count
- DJCO 0
- WVE 11
- Target Price
- DJCO N/A
- WVE $20.91
- AVG Volume (30 Days)
- DJCO 6.6K
- WVE 1.7M
- Earning Date
- DJCO 05-20-2025
- WVE 05-08-2025
- Dividend Yield
- DJCO N/A
- WVE N/A
- EPS Growth
- DJCO 370.42
- WVE N/A
- EPS
- DJCO 55.48
- WVE N/A
- Revenue
- DJCO $71,642,000.00
- WVE $104,939,000.00
- Revenue This Year
- DJCO N/A
- WVE N/A
- Revenue Next Year
- DJCO N/A
- WVE N/A
- P/E Ratio
- DJCO $7.06
- WVE N/A
- Revenue Growth
- DJCO 0.34
- WVE N/A
- 52 Week Low
- DJCO $359.34
- WVE $4.25
- 52 Week High
- DJCO $602.00
- WVE $16.74
- Technical
- Relative Strength Index (RSI)
- DJCO 57.11
- WVE 43.25
- Support Level
- DJCO $367.24
- WVE $5.62
- Resistance Level
- DJCO $381.31
- WVE $6.73
- Average True Range (ATR)
- DJCO 7.42
- WVE 0.60
- MACD
- DJCO 2.60
- WVE 0.07
- Stochastic Oscillator
- DJCO 100.00
- WVE 36.10
About DJCO Daily Journal Corp. (S.C.)
Daily Journal Corp publishes newspapers and websites covering California and Arizona and produces several specialized information services. The company operates in two segments: Traditional business and Journal Technologies. It also serves as a newspaper representative specializing in public notice advertising. The majority of revenue is generated from the Journal Technologies segment.
About WVE Wave Life Sciences Ltd.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.